<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00422448</url>
  </required_header>
  <id_info>
    <org_study_id>V9-B05 (FWF)</org_study_id>
    <nct_id>NCT00422448</nct_id>
  </id_info>
  <brief_title>Study to Test Genetic Alterations Among Different Dermoscopic Types of Melanocytic Nevi.</brief_title>
  <official_title>BRAF and Nevi.Nevi Are Common Benign Pigmented Tumors of the Skin. Mutations in So-called BRAF and NRAS Genes Genes Appear to be Initiating Events Responsible for the Formation of Nevi.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Graz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Graz</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project is a multicenter study in which we will investigate a dual concept of
      nevogenesis. Study location is the Department of Dermatology at the Medical University of
      Graz in collaboration with centers in Austria (Vienna), Italy (Naples, Benevento, Modena),
      Spain (Barcelona) and the United States (New York).

      The hypothesis is that small congenital melanocytic nevi (CMN), &quot;early&quot; acquired melanocytic
      nevi in childhood (AMN) and dermal nevi, all dermatoscopically characterized by globular
      pattern, belong to the same spectrum of genetically determined melanocytic proliferations
      that develop due to endogenous pathways, in contrast to &quot;true&quot; acquired melanocytic nevi,
      dermatoscopically showing reticular pattern, that develop due to exogeneous factors such as
      UV-exposure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigations to this study will verify whether small CMN, &quot;early&quot; AMN and dermal nevi,
      characterized by globular pattern differ in their genetic alterations compared to reticular
      typed nevi. It will be expected that globular typed nevi and eventually dermal nevi lack
      B-RAF mutations whereas reticular nevi show alterations in the B-RAF gene. Study location:
      Graz
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of BRAF Mutations Among Nevi</measure>
    <time_frame>up to 30 months</time_frame>
    <description>All nevi were analyzed for BRAF mutations using the (less sensitive) Sanger method. A random subset of nevi was also analyzed using the (more sensitive) Ultradeep pyro-sequencing method (UDPS). The frequency is reported here as the number of BRAF mutations found by each method.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of NRAS Mutations Among Nevi</measure>
    <time_frame>30 months</time_frame>
    <description>All nevi were analyzed for NRAS mutations using the (less sensitive) Sanger method. The (more sensitive) Ultradeep pyro-sequencing method (UDPS) is not applicable for this mutation. The frequency is reported here as the number of NRAS mutations from the analyzed nevi.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Nevi</condition>
  <arm_group>
    <arm_group_label>Nevi from participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Benign nevi dermoscopically sub-classified into 4 dermoscopic types (i.e., with globular, reticular, mixed pattern with globules in the center and mixed pattern with globules at the periphery) were excised from healthy volunteers for further genetical analysis</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>To test the frequency of BRAF and NRAS mutations among nevi</intervention_name>
    <description>Benign nevi excised for the study purpose where genetically analyzed for the presence/absence of BRAF and NRAS mutations</description>
    <arm_group_label>Nevi from participants</arm_group_label>
    <other_name>NM_004333; Homo sapiens v-raf murine sarcoma viral oncogene homolog B1</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy individuals aged 9 to 80 years showing one or more dermoscopically benign nevi
             with either uniform globular-cobblestone pattern or reticular pattern or a combination
             of both types

        Exclusion Criteria:

          -  Children under the age of 9 years

          -  Pregnant woman

          -  Patients with atypical nevi (i.e., melanoma cannot be clinically ruled out)

          -  Patients with immunosuppression

          -  Patients with sun exposure 4 weeks before enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Iris Zalaudek, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Dermatology, Medical University of Graz</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Dermatology, Medical University of Graz</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <link>
    <url>http://www.fwf.ac.at/</url>
    <description>Webpage of the sponsoring organization</description>
  </link>
  <reference>
    <citation>Zalaudek I, Grinschgl S, Argenziano G, Marghoob AA, Blum A, Richtig E, Wolf IH, Fink-Puches R, Kerl H, Soyer HP, Hofmann-Wellenhof R. Age-related prevalence of dermoscopy patterns in acquired melanocytic naevi. Br J Dermatol. 2006 Feb;154(2):299-304.</citation>
    <PMID>16433800</PMID>
  </reference>
  <reference>
    <citation>Zalaudek I, Hofmann-Wellenhof R, Soyer HP, Ferrara G, Argenziano G. Naevogenesis: new thoughts based on dermoscopy. Br J Dermatol. 2006 Apr;154(4):793-4.</citation>
    <PMID>16536840</PMID>
  </reference>
  <verification_date>December 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 15, 2007</study_first_submitted>
  <study_first_submitted_qc>January 16, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 17, 2007</study_first_posted>
  <results_first_submitted>April 25, 2010</results_first_submitted>
  <results_first_submitted_qc>December 14, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 14, 2011</results_first_posted>
  <last_update_submitted>December 14, 2010</last_update_submitted>
  <last_update_submitted_qc>December 14, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 14, 2011</last_update_posted>
  <responsible_party>
    <name_title>Department of Dermatology, Medical University of Graz Austria</name_title>
    <organization>Iris Zalaudek</organization>
  </responsible_party>
  <keyword>Dermoscopy</keyword>
  <keyword>Histopathology</keyword>
  <keyword>Genetics</keyword>
  <keyword>Nevi</keyword>
  <keyword>Nevogenesis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nevus</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Pigmented lesion clinic from October 2006 to March 2009</recruitment_details>
      <pre_assignment_details>Insufficient prospective accrual of patients during the 1st year of enrollment lead to additional retrospective inclusion of a dataset of 21 paraffin-embedded tissue specimens from excised nevi .</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Nevi</title>
          <description>with or without BRAF and NRAS</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="43">22 prospectively enrolled during study period and 21 retrospectively enrolled</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Nevi</title>
          <description>with or without BRAF and NRAS</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="43"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.3" spread="9.413"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Frequency of BRAF Mutations Among Nevi</title>
        <description>All nevi were analyzed for BRAF mutations using the (less sensitive) Sanger method. A random subset of nevi was also analyzed using the (more sensitive) Ultradeep pyro-sequencing method (UDPS). The frequency is reported here as the number of BRAF mutations found by each method.</description>
        <time_frame>up to 30 months</time_frame>
        <population>All nevi were analyzed for BRAF mutations using the (less sensitive) Sanger method. A random subset of nevi was also analyzed using the (more sensitive) Ultradeep pyro-sequencing method (UDPS). The frequency is reported here as the number of BRAF mutations found by each method.</population>
        <group_list>
          <group group_id="O1">
            <title>Nevi</title>
            <description>with or without BRAF and NRAS</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of BRAF Mutations Among Nevi</title>
          <description>All nevi were analyzed for BRAF mutations using the (less sensitive) Sanger method. A random subset of nevi was also analyzed using the (more sensitive) Ultradeep pyro-sequencing method (UDPS). The frequency is reported here as the number of BRAF mutations found by each method.</description>
          <population>All nevi were analyzed for BRAF mutations using the (less sensitive) Sanger method. A random subset of nevi was also analyzed using the (more sensitive) Ultradeep pyro-sequencing method (UDPS). The frequency is reported here as the number of BRAF mutations found by each method.</population>
          <units>BRAF mutations</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>nevi</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sanger method (n=45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UDPS (n=24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of NRAS Mutations Among Nevi</title>
        <description>All nevi were analyzed for NRAS mutations using the (less sensitive) Sanger method. The (more sensitive) Ultradeep pyro-sequencing method (UDPS) is not applicable for this mutation. The frequency is reported here as the number of NRAS mutations from the analyzed nevi.</description>
        <time_frame>30 months</time_frame>
        <population>All nevi were analyzed for NRAS mutations using the (less sensitive) Sanger method. The (more sensitive) Ultradeep pyro-sequencing method (UDPS) is not applicable for this mutation. The frequency is reported here as the number of NRAS mutations from the analyzed nevi.</population>
        <group_list>
          <group group_id="O1">
            <title>Nevi</title>
            <description>with or without BRAF and NRAS</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of NRAS Mutations Among Nevi</title>
          <description>All nevi were analyzed for NRAS mutations using the (less sensitive) Sanger method. The (more sensitive) Ultradeep pyro-sequencing method (UDPS) is not applicable for this mutation. The frequency is reported here as the number of NRAS mutations from the analyzed nevi.</description>
          <population>All nevi were analyzed for NRAS mutations using the (less sensitive) Sanger method. The (more sensitive) Ultradeep pyro-sequencing method (UDPS) is not applicable for this mutation. The frequency is reported here as the number of NRAS mutations from the analyzed nevi.</population>
          <units>NRAS mutations</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>number of nevi</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>were not collected or assessed</time_frame>
      <desc>postoperative complications were not collected or assessed</desc>
      <group_list>
        <group group_id="E1">
          <title>Nevi</title>
          <description>with or without BRAF and NRAS</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>During first year of enrollment too few patients agreed to participate. Therefore a sample of 21 nevi were additionally retrospectively included.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Prof. Dr. Iris Zalaudek</name_or_title>
      <organization>Medical University of Graz - Austria</organization>
      <phone>+436763328269</phone>
      <email>iris.zalaudek@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

